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Abstract Hereditary sensory neuropathy type 1 (HSAN I)
is an autosomal dominant inherited neurodegenerative
disorder of the peripheral nervous system associated with
mutations in the SPTLC1 subunit of the serine palmitoyl-
transferase (SPT). Four missense mutations (C133W,
C133Y, V144D and G387A) in SPTLC1 were reported to
cause HSAN I. SPT catalyses the condensation of Serine
and Palmitoyl-CoA, which is the first and rate-limiting step
in the de novo synthesis of ceramides. Earlier studies
showed that C133W and C133Y mutants have a reduced
activity, whereas the impact of the V144D and G387A
mutations on the human enzyme was not tested yet. In this
paper, we show that none of the HSAN I mutations
interferes with SPT complex formation. We demonstrate
that also V144D has a reduced SPT activity, however to a
lower extent than C133W and C133Y. In contrast, the
G387A mutation showed no influence on SPT activity.
Furthermore, the growth phenotype of LY-B cells—a
SPTLC1 deficient CHO cell line—could be reversed by
expressing either the wild-type SPTLC1 or the G387A
mutant, but not the C133W mutant. This indicates that the
G387A mutation is most likely not directly associated with
HSAN I. These findings were genetically confirmed by the
identification of a nuclear HSAN family which showed
segregation of the G387A variant as a non-synonymous SNP.
Keywords HSAN I . Peripheral neuropathy . SPTLC .
Serine palmitoyltransferase . Sphingolipid . Ceramide
Introduction
Hereditary sensory (and autonomic) neuropathy type 1
(HSN1 or HSAN I) is the most frequent HSAN subtype
predominantly affecting the distal lower extremities [1].
Symptoms begin with loss of pain and temperature
sensation in feet and hands, often complicated by severe
infections, which can finally lead to osteomyelitis and
amputations. As the disease progresses, there is degenera-
tion of motor neurons with secondary denervation, atrophy
and weakness of distal limb muscles. The mode of
inheritance is autosomal dominant, with a typical onset in
the second or third decade [2]. These features are
characteristically associated with spontaneous, lancinating,
pain attacks and deafness in some families [1]. The genetic
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locus for HSAN I maps to chromosome 9q22, and
positional cloning subsequently identified mutations in the
SPTLC1 gene [3, 4]. Four missense mutations (C133W,
C133Y, V144D, G387A) were identified in a total of 24
HSAN I families (www.molgen.ua.ac.be/CMTMutations/)
[3–5].
The SPTLC1 gene encodes for the first of the three
subunits (SPTLC1, SPTLC2 and SPTLC3) of the serine
palmitoyltransferase (SPT). SPT catalyses the pyridoxal-
phosphate (PLP)-dependant condensation of L-serine and
palmitoyl-CoA which is the initial and rate-limiting step in
the de novo synthesis of sphingolipids [6]. The two
subunits SPTLC1 and SPTLC2 have a mutual similarity
of 20% and are highly conserved among species. The
recently identified third subunit (SPTLC3) shows 86%
similarity to SPTLC2 and has a more tissue-specific
distribution with very high expression levels in placenta
[7]. SPTLC1 and at least one of the other two subunits are
required for enzyme activity. SPTLC2 and SPTLC3 are
hereby considered to be the catalytic subunits due to the
presence of a PLP binding motive, which is absent in
SPTLC1. The singular overexpression of SPTLC1 subunit
does not change SPT activity, whereas the overexpression
of the SPTLC2 or SPTLC3 subunit leads to a significant
increase in cellular SPT activity [7, 8]. However, structural
data indicate that the active site in SPT is located at the
monomer–monomer interface and that a part of the active
site is also formed by the SPTLC1 subunit [9].
Several in vitro studies show a significantly reduced SPT
activity for the SPTLC1-C133W and -C133Y mutant [10–
12]. For the yeast enzyme, a reduced activity was reported
after introducing the V144D mutation [12]. The impact of
the G387A and V144D mutation on the mammalian SPT
was not investigated so far.
In this work, we intended to compare the influence of all
reported HSAN I mutations on human SPT complex
formation and enzyme activity to gain a better insight into
the pathomechanism of this disease.
Materials and methods
Clinical data Patient CMT-820.01 is a 1-year-old child
born to non-consanguineous healthy parents of Moroccan
origin. The patient presented at 1 year of age with painless
injuries and burns and intermitting fever episodes. The
child reacts to touch, but shows insensitivity to pain stimuli.
The patient developed normally. Reflexes are symmetrical-
ly low in arms and normal in legs. Electromyogram study
revealed a mild, mainly sensory polyneuropathy. Informed
consent was obtained from the participants and approved by
the Institutional Review Board and Ethics Committees of
the universities involved in this study.
Mutation analysis The coding regions and exon–intron
boundaries of SPTLC1 were polymerase chain reaction
(PCR)-amplified using intronic primers as described previ-
ously [5]. Mutation screening was performed by direct
sequencing of purified PCR fragments using the BigDye
Terminator v3.1 cycle sequencing kit and an ABI 3730
automated capillary DNA sequencer (Applied Biosystems).
The resulting sequence trace files of SPTLC1 were aligned
according to the NM_006415 sequence (NCBI) and
analysed using the novoSNP program [13]. The mutation
and the segregation in the family was confirmed by PCR–
restriction fragment length polymorphism (PCR-RFLP)
analysis using the EciI restriction enzyme (New England
Biolabs)
Paternity testing Paternity was tested in family CMT-820
using 15 highly informative STRs distributed throughout
the genome (ATA38A05, D1S1646, D1S1653, D1S1360,
D2S2256, D3S3037, D4S2382, D4S3240, D7S509,
D8S1759, D9S1118, D12S1056, D12S2082, D16S2619
and GATA152H04). STRs were PCR-amplified and PCR
fragments were resolved on an ABI 3730 automated DNA
sequencer. Genotypes were analysed using the ABI Prism
Genescan software (Applied Biosystems) and Local Geno-
type Viewer, an in-house developed software program
(http://www.vibgeneticservicefacility.be/).
Cloning The SPTLC1 and SPTLC2 cDNA was amplified
from a human cDNA library and cloned into a
pcDNA3.1D/V5-His vector as described earlier [7]. The
HSAN I mutations were introduced by site-specific muta-
genesis. The following primers were used for cloning:
SPTLC1C133Wfw: 5′-ggggacccagaggattttatggcacattt
gatgttc-3′
SPTLC1C133Yfw: 5′-atggtcctcgaggattttatggcacattt
gatgttc-3′
SPTLC1V144Dfw: 5′-gtggacccagaggattttatggcacattt
gatgatcatttggatttggaagaccg-3′
SPTLC1C133W/C133Y/V144Drv: 5′-aggtacccacgcca
tacttctttagagatgctaaagc-3′
SPTLC1G387Afw: 5′-aagtggtggcggagtccctttctccagccttt
cacct-3′
SPTLC1G387Arv: 5′-ttaatccagatatcccttgtaaagctttat
gaatttgtcc-3′.
All constructs were subsequently validated by sequencing
(ABIPRISM™ 310 Genetic Analyser, Perkin Elmer).
Cell lines HEK293 and CHO-K1 cells were obtained from
ATCC. The LY-B cell line was a gift from Dr. Kentaro
Hanada (National Institute of Infectious Disease, Tokyo,
Japan).
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HEK293 cells were cultured in Dulbecco’s modified
Eagle’s medium (Sigma) containing 10% fetal bovine serum
(Fischer Scientific) and penicillin/streptomycin (100 U per
ml/0.1 mg per ml). CHO-K1 and LY-B cells were maintained
in Ham’s F-12 medium (Sigma) containing 10% fetal bovine
serum (Fischer Scientific) and penicillin/streptomycin (100 U
per ml/0.1 mg per ml, Sigma).
Stable overexpressing cell lines HEK293 and LY-B cells
were transfected with lipofectamine 2000 (Invitrogen)
according to the manufacturers’ instructions. The trans-
fected cells were selected with G418 (400 μg ml−1) and the
expression confirmed by Western blot analysis.
Lymphoblastoid cell lines Blood samples of HSAN I
patients were added to 15 ml of Ficol Paque and centrifuged
for 10 min. After washing, lymphocytes were resuspended in
5 ml Epstein–Barr virus (EBV) and incubated at 37°C for
2 h. After centrifugation, the pellet was resuspended in 4 ml
RPMI1640 complete medium + 1% phytohaemagglutinin.
Cells were seeded in a 24-well plate and incubated at 37°C
and 6% CO2 for more than 3 days. EBV-infected cultures
were observed for the appearance of clusters indicative of
transformation. Cells were split and supplemented with fresh
medium as needed.
Western blot For Western blot analysis, protein samples
were supplemented with sodium dodecyl sulphate (SDS)
loading buffer and separated by SDS–polyacrylamide gel
electrophoresis (SDS-PAGE; 10% acrylamide) and blotted
to a polyvinylidene fluoride (PVDF) membrane (Amer-
sham). The membrane was blocked in Tris-buffered saline
containing 0.1% Tween 20 and 5% low-fat milk powder.
SPTLC1 and SPTLC2 were detected using a polyclonal
rabbit serum [7]. Beta-actine and the V5-TAG were
detected by commercial mouse monoclonal antibodies
(Serotec). The antibodies were detected with a secondary
anti-mouse/rabbit HRPO conjugate using ECL plus (Amer-
sham) luminescence substrate. For the densitomeric analy-
sis, the ECL reaction was directly recorded on a image
analyser (Kodak Image Station 4000 MM pro) and the
signal quantified using the Kodak Imaging Software.
Immunoprecipitation Cells were harvested at 70–80% con-
fluency. The medium was removed and the cells washed
twice with ice-cold phosphate-buffered saline (PBS). All
steps were performed at 4°C. Cells were lysed in HT buffer
[25 mM HEPES pH 8.0, 0.2% Triton X100, Protease-
Inhibitors (Roche)] for 15 min followed by sonication (15 s,
50%, 0.5-s interval). Insoluble cell debris was removed by
centrifugation (13,000×g, 5 min at 4°C). The precipitation
was performed by adding 25 μl anti V5-agarose beads
(Sigma). The beads were washed three times for 10 min in
HT buffer (rolling at 4°C) and the bound protein eluted by
adding an excess of free V5 peptide (10 mg/ml, incubated
for 1 h at 4°C). The eluted proteins were separated by 12%
SDS/PAGE, blotted to a PVDF membrane and the
precipitated SPT subunits detected by Western blot.
Preparation of cell lysate Cells were grown on 10-cm
dishes to approximately 80% confluency. Medium was
removed and the cells were washed two times with PBS
and harvested in 1 ml of PBS by scraping. The suspension
was transferred into a 1.5-ml reaction tube. The cells were
precipitated by centrifugation (2,500×g, 2 min at 4°C) and
resolved in HT buffer [50 mM HEPES–NaOH buffer
(pH 8.0), 0.2% Triton X100]. Non-solubilised components
were removed by centrifugation (16,000×g, 5 min at 4°C).
The protein concentration was adjusted to 4 mg/ml. Protein
concentrations of the cell lysates were determined using the
Bradford Assay (Bio-Rad). Albumin was used as a
standard.
SPT Activity Assay For measuring the in vitro SPT activity,
we used an improved protocol based on the published
method from Dickson et al. [14]. The major alterations are
the use of total cell extract instead of microsomes and the
addition of 0.2% sucrose monolaurate (SML). The addition
of SML results in a significantly higher specific SPT
activity due to the inhibition of the interfering thioesterases
background activity. Under these assay conditions, SPT
activity is linear for more than 60 min, which leads to
higher signals and a significantly improved signal to noise
ratio. A detailed protocol about the assay is in preparation
and will be published elsewhere. Typically, a reaction
cocktail was composed of 400 μg total cell lysate, 50 mM
HEPES (pH 8.0), 0.5 mM L-serine, 0.05 mM Palmitoyl-
CoA, 20 μM Pyridoxal-5′-phosphate, 0.2% SML (Sigma),
0.1 μCi L-[U-14C] serine (Amersham) in a total volume of
200 μl. The assay was performed at 37°C for 60 min. For
the controls, SPT activity was specifically blocked by the
addition of the SPT inhibitor myriocin (40 μM, Sigma).
The reaction was stopped by adding 0.5 ml methanolic
KOH/CHCl3 (4:1) to the mixture. Methanolic KOH was
prepared by dissolving 0.7 g KOH platelets in 100 ml
MetOH. Lipids were extracted at 37°C under steady
agitation for 30 min. Subsequently, 500 μl CHCl3, 500 μl
alkaline water [100 μl NH4 (2 N) in 100 ml H2O] and
100 μl NH4 (2 N) were added in this order. Phases were
separated by centrifugation (13,000×g, 5 min) and the
upper phase removed. The lower phase was washed three
times with alkaline water. Finally, the lower organic phase
was transferred to a scintillation vial and the CHCl3
evaporated under a N2 steam. After the addition of
scintillation cocktail, the radioactivity was quantified on a
Scintillation Analyser (Packard Liquid 1900TR).
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Quantitative RT-PCR The mRNA was prepared using Tri
Reagent (Molecular Research Center, Cincinnati, USA) and
transcribed to cDNA using oligo dT primers and Superscript
III (Invitrogen) according to the manufacturer’s instructions.
Specific primers for the different SPT subunits were designed
using the Oligo6.0 software (Molecular Biology Insights,
Cascade, USA). The housekeeping gene GAPDH was used
as the reference gene for quantification. Light cycler PCR
was performed with a DNA Sybr-Green kit following the
manufacturer’s instructions (Roche Diagnostics, Basle). The
following primers (0.4 μM each) were used:
SPTLC1fw: 5′-aagaagccattatatactcatat-3′; SPTLC1rv:
5′-ggcactgataagatcaata-3′
SPTLC2fw: 5′-gagtgtgtacaacagttagctg-3′; SPTLC2rv:
5′-tggctcacaaaggccac-3′.
Amplification was carried out for SPTLC1: 40 cycles,
each consisting of 10 s at 95°C; 10 s at 58°C; 20 s at 72°C.
SPTLC2: 40 cycles, each consisting of 10 s at 95°C; 10 s at
58°C; 20 s at 72°C. The linearity of the assays was
determined by serial dilutions of the templates.
Quantification of free sphingosine bases by HPLC Cells
were cultured until they reach 60–80% confluency. Lipids
were extracted in the presence of the internal standard
followed by an acid and base hydrolysation and quantified
as OPA derivates by high-performance liquid chromatogra-
phy (HPLC) and fluorescence detection. This method is
based on the published protocol from Riley et al. [15].
LY-B rescue assay Stably transfected LY-B cells were
seeded at a density of 7,500 cells per well in a 12-well
dish. The cells were cultured overnight in Ham’s F-12
medium containing 10% foetal calf serum and penicillin/
streptomycin. After 24 h, the cells were washed three times
with PBS and the medium exchanged to Ham’s F-12
containing 1% Nutridoma-SP (Roche). After culturing the
cells for 7 days, the cells were washed three times in PBS,
trypsinised and counted on a coutler® Z2 cell counter
(Beckman Coulter).
Results
Expression of HSAN I mutants of SPTLC1 in HEK293
cells
The SPTLC1 cDNA was amplified out of a commercial
human cDNA library and cloned into a pcDNA3.1 expres-
sion vector with the fusion of a C-terminal V5-HIS tag. The
four HSAN I mutations, C133W, C133Y, V144D and
G387A, were introduced by site-directed mutagenesis and
the constructs transfected into HEK293 cells. Transfected
cells were selected for antibiotic resistance to generate a pool
of stably expressing cells. The expressed proteins were
analysed by Western blot. The polyclonal SPTLC1 antibody
shows a band doublet due to the mass addition of tag
sequences. The lower band corresponds to the endogenous
wild-type SPTLC1 and the upper band to the transfected
SPTLC1 subunit (Fig. 1a). The densitometric quantification
revealed no differences in the expression levels between the
individual mutants. Compared to the endogenous SPTLC1
subunit, we observed a three to fivefold higher expression of
the mutant. The overexpression of the SPTLC1 mutants had
no influence on the expression levels of the endogenous
SPTLC1 and SPTLC2 subunits (Fig. 1a).
All SPTLC1-HSAN I subunits interact with the SPTLC2
subunit
To see whether the SPTLC1-HSAN Imutations are interfering
with the formation of a functional SPT complex, we
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Fig. 1 a Western blot of HEK293 cells expressing either the empty
vector, the wild-type SPTLC1 or the SPTLC1–HSAN I mutants. The
transfected subunits were detected by a V5-tag antibody and a
polyclonal SPTLC1 antibody. The polyclonal SPTLC1 antibody
showed a band doublet due to the mass addition of the fused V5-
Tag. The overexpression of SPTLC1 had no influence on the
expression levels of the endogenous SPTLC1 and SPTLC2 subunit.
Beta-actin immunostaining was used as a loading control. b
Immunoprecipitation of the SPT complex in SPTLC1-HSAN I
overexpressing HEK293 cells. The expressed SPTLC1 subunits were
specifically precipitated with an anti V5-antibody and the precipitate
probed for the co-precipitation of SPTLC2. All HSAN I mutants could
be precipitated (upper panel) and showed a concomitant pull down of
SPTLC2 (lower panel)
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performed co-immunoprecipitation studies. The transfected
SPTLC1 mutants were specifically targeted with an anti V5-
tag antibody and the precipitate probed for the co-precipitation
of SPTLC2. The wild-type SPTLC1 and all mutants showed a
concomitant pull down of the SPTLC2 subunit (Fig. 1b). No
precipitate was seen in control cells expressing the empty
vector. This shows that none of the HSAN I mutations is
interfering with the SPT complex formation.
SPT activity in HEK-HSAN I cells and HSAN I
lymphoblasts
The influence of the HSAN I mutations on SPT activity was
determined by measuring the incorporation of 14C labeled
L-serine in vitro. The singular overexpression of the wild-
type SPTLC1 subunit did not influence SPT activity
(Fig. 2a), which is in agreement with earlier results [7]. In
contrast, the overexpression of the C133W and C133Y
mutant leads to a 50% reduced SPT activity (Fig. 2a). A
reduced activity was also observed in V144D-expressing
cells. Here, SPT activity was about 40% reduced (Fig. 2a).
Surprisingly, no change in activity was observed for the
G387A-expressing cells. The SPT activity in these cells was
the same as in the wild-type cells (Fig. 2a).
However, the overexpression of a mutant SPTLC1 in the
usual physiological context of a normal wild-type allele
might not represent the situation found in HSAN I patients
where only one allele is mutated. Therefore, we validated
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Fig. 2 a In vitro SPT activity in HSAN I mutant overexpressing
HEK293 cells and EBV-transformed lymphoblast lines from HSAN I
patients. SPT activity was significantly reduced in the HEK293 cells
which expressed the C133W, C133Y and V144D mutant. Activity was
unaltered in cells which expressed the wild-type SPTLC1 or the
G387A variant. The activity in EBV-transformed lymphoblasts
showed a different picture. Activity was less prominently reduced in
the C133W lymphoblasts compared to the control lines Cntr.1 and
Cntr.2. Moreover, the G387A(1) line from sister 1 showed an almost
doubled activity compared to the cell line from sister 2. SPT activity in
the G387A(2) line was comparable to the controls. b mRNA
expression levels of SPTLC1 (grey) and SPTLC2 (black) in EBV-
transformed HSAN I lymphoblasts. SPTLC1 mRNA expression levels
were generally higher than those for SPTLC2 but not changed
between the cell lines. In contrast, SPTLC2 expression levels were
significantly higher in the C133W and the G387A(1) cells compared
to the other lymphoblasts lines. For comparison, mRNA levels were
normalised to GAPDH expression. c In vitro SPT activity in EBV
transformed lymphoblast after normalisation to the SPTLC2 mRNA
levels. The differences in SPT activity seen between G387A(1) and
G387A(2) were leveled out after normalisation. The C133W line
showed a more pronounced activity reduction, similar to the activity
seen in the HEK293-C133W cells
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these results in EBV-transformed lymphoblasts from HSAN
I patients. We tested cell lines obtained from patients with a
C133W and a V144D mutation and two lines from the
Belgian HSAN twins (family CMT-155) in which the
G387A mutation was originally reported [5]. A lympho-
blast line from a C133Y carrier was not available.
Like for the mutant expressing HEK293 cells, we
observed a reduced in vitro SPT activity in the cell lines
from patients with C133W and V144D mutation compared
to cells from unaffected controls. However, the C133W
mutation seemed to have a milder impact on SPT activity in
the C133W lymphoblast line compared to HEK-C133W
cells (Fig. 2a). Interestingly, the two G387A lines showed
contradictory results, whereas the cells from patient 1
[G387A(1)] showed a twofold increased SPT activity; the
activity in the cells from patient 2 [G387A(2)] was similar to
the controls (Fig. 2a). To address this discrepancy, we
compared the SPTLC1 and SPTLC2 mRNA expression
levels between the individual lymphoblast lines. Quantitative
real-time PCR (RT-PCR) analysis revealed similar mRNA
levels for SPTLC1 in all cell lines (Fig. 2b). However, the
SPTLC2 mRNA levels were twofold higher in the C133W
and G387A(1) cells compared to the other lines [Cntr.1,
Cntr.2, V144D and G387A(2)]. This increased SPTLC2
expression in the C133W and G387A(1) lines could also be
confirmed on the protein level by Western blot (data not
shown). This suggests that the increased SPT activity in the
C133W and the G387A(1) lymphoblast lines is caused by
the augmented expression of SPTLC2 in these cells. The
reason for this SPTLC2 overexpression is not clear but could
possibly be caused by the previously performed EBV
transformation. After the normalisation of SPT activity to
the SPTLC2 mRNA expression levels, the differences
between the two G387A lines are leveled out (Fig. 2c).
Also, the C133W line showed a more significantly reduced
SPTactivity after normalisation, similar to C133W-expressing
HEK293 cells.
Total sphingolipid levels are not altered in HSAN I
lymphoblasts
It can be assumed that the reduced SPT activity, seen with
the C133W and V144D lymphoblasts, also results in a
reduced de novo synthesis and consequently in a reduced
total sphingolipid content in these cells. We therefore
extracted the total cellular lipids from the HSAN I
lymphoblasts and subjected them to an acid and base
hydrolysis. The hydrolysis under acidic conditions led to
a disruption of the N-linked fatty acid and the subsequent
basic hydrolysis to a release of the O-linked phosphate or
carbohydrate group from the sphingosine backbone. The
amount of free sphingosine was analysed by HPLC and
reflected the total sphingolipid content of the cells. The
concentrations of dihydro-sphingosine (sphinganine) were
negligible. Although both, the C133W and V144D
lymphoblast line, showed an about 50% reduced SPT
activity, we did not observe significant changes in the total
sphingosine content between the HSAN I cells and the
controls (Fig. 3b).
The G387A mutant can reverse the phenotype
of an SPTLC1-deficient cell line
The reduced SPT activity seen in HSAN I patients is widely
considered to be the pathophysiological background of
HSAN I. However, this view is challenged by the
observation that the G387A mutation has no impact on
SPT activity. Nevertheless, the clinical symptoms of the
affected sisters were reported to be typical for the HSAN I
phenotype, including the presence of lancinating pain
attacks which are considered as a hall mark for HSAN I.
Although the G387A mutation has no impact on enzyme
activity, there is still the possibility that this mutation
induces other cytotoxic effects like protein aggregation or
the formation of a toxic side product. To test this
hypothesis, we overexpressed the G387A mutant in LY-B
cells [6]. LY-B cells are mutant CHO cells which are
deficient in SPT activity and de novo sphingolipid synthesis
[16]. This is due to a spontaneous G246R missense
mutation in the SPTLC1 subunit which renders this subunit
to be unstable [17]. LY-B cells are therefore dependant on
the presence of an exogenous sphingolipid source. Suffi-
cient amounts of sphingolipids are usually provided by the
added serum in the culture medium. In contrast, LY-B cells
are not able to survive when the serum is replaced by a
defined lipid-free serum substitute like Nutridoma SP [16].
The transfection and expression of a functional SPTLC1
subunit in LY-B cells rescues this phenotype and restores
growth also in a sphingolipid-deficient medium [6]. Since
the G387A mutant shows a normal in vitro activity, we
presumed that this mutant should also be able to rescue the
phenotype of the LY-B cells if no other cytotoxic side
products are generated. We therefore expressed the G387A
mutant in LY-B cells and compared the growth to SPTLC1
wild-type and C133W-expressing LY-B cells. The survival
rate of the cells was analysed after cultivation for 7 days in a
sphingolipid-free medium (Nutridoma SP, 1%). Untrans-
fected LY-B cells were not able to grow under these
conditions, whereas in SPTLC1-transfected cells, growth
was restored and comparable to the CHO wild-type cells
(Fig. 3a). The expression of the C133W mutant did not
restore growth. In contrast, the expression of G387A resulted
in the formation of a functional SPT enzyme and growth was
fully restored. This demonstrates that the enzymatic activity
of G387A is normal and sufficient to restore the de novo
synthesis in the LY-B cells. It furthermore shows that the
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expression of G387A does not induce significant toxic side
effects even when the cell is fully dependent on the
endogenous production of sphingolipids.
The G378A missense mutation in SPTLC1 is not
necessarily associated with HSAN I
These biochemical results were finally confirmed geneti-
cally. We identified a female patient (CMT-820.01) diag-
nosed with a HSAN phenotype (Fig. 4a). This patient
carried the same c.1160G>A variation as it was originally
described in the Belgian twin sisters. This sequence
variation was originally tested and found to be absent in a
total of 200 unrelated control individuals. However,
segregation analysis in the patients’ family showed that
her unaffected mother (CMT-820.03) carries the sequence
variant in the homozygous state (Fig. 4b). Her father (CMT-
820.2), also unaffected, carries the wild-type allele. The
genetic relationship between the mother, father and their
affected child was confirmed by screening a set of highly
informative STR markers (data not shown).
Discussion
Initially, three SPTLC1 missense mutations (C133W,
C133Y and V144D) have been reported to cause HSAN I.
Later, a fourth mutation (G387A) was identified in a HSAN
I family with affected twins [5]. Both patients had a typical
HSAN I phenotype, including the presence of spontaneous
pain attacks which is believed to be a hallmark for HSAN I.
An unaffected relative did not carry the mutation.
It was previously shown that the C133W and C133Y
mutations result in a decreased enzymatic activity [10–12].
In the present work, we showed that the same is true for
the, not yet characterised, human V144D mutation. We
therefore expected that in analogy to the other HSAN I
mutants, also the G387A has an impaired activity. Surpris-
ingly, we did not observe any changed enzymatic activity of
this mutant. This was tested in G387A overexpressing
HEK293 cells, but also observed in the EBV-transformed
primary lymphoblast of the affected twins. The discrep-
ancies seen for the C133W and the G387A(1) lymphoblast
lines could be explained by the elevated SPTLC2 expres-
sion levels in these cells. In line with these results is the
observation that the expression of G387A in the SPTLC1-
deficient LY-B cells fully reverses the phenotype of these
cells. This shows furthermore that the expression of the
G387A mutant is also not toxic to the cell by other means.
In the light of these findings, the G387A mutation is just
a benign variant of SPTLC1 and not directly disease-
causing. This is further supported by the observation that
this sequence variant is found in the homozygous state in
the unaffected mother (CMT-820.03) of a HSAN patient
(CMT-820.01). Nevertheless, it is notable that three patients
with that specific sequence variation were identified by
showing clinical signs of a HSAN like phenotype. This
G387A mutation was found in one case out of a collective
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Fig. 3 a Restoring de novo sphingolipid synthesis in LY-B cells.
Cells were stably transfected with the wild-type SPTLC1, C133W and
G387A. Total cell number per dish was determined after cultivating
the cells for 7 days under sphingolipid deficient conditions (Nutri-
doma-SP). Whereas CHO wild-type cells could grow under these
conditions, the SPTLC1-deficient LY-B cells were not able to survive
without the supplementation of external sphingolipids. The transfec-
tion of the wild-type SPTLC1 subunit, but not of the inactive C133W
mutant, completely reversed this restriction. Both, wild-type SPTLC1
and G387A mutant expressing LY-B cells were able to grow under
these conditions. b Total sphingosine concentration in transformed
HSAN I lymphoblast. Total lipids were extracted and subjected to an
acid and base hydrolysis. The total sphingosine content was analysed
by HPLC and normalised to cell number and C17 sphingosine, which
is added as an internal standard. No significant differences in the total
SO content was observed between HSAN I and control lines
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of 390 unaffected controls, indicating that it is not a
frequent polymorphism. It might therefore be possible that
the G387A itself is not disease-causing but has a bystander
effect by increasing the risk to develop a HSAN phenotype
in conjunction with another, not yet identified, mutation.
The molecular background of HSAN I is still unclear
and published results are largely inconclusive and contra-
dictory. Initially, an increase in glucosylceramide synthesis
was described [4], whereas subsequently, a decreased
ceramide and sphingomyelin synthesis [10, 12] and later
an unchanged lipid composition was reported [11]. The
latter finding is also confirmed by our own results.
Interestingly, transgenic SPTLC1-C133W mice show a
decreased in vitro SPT activity and develop age-dependent
motor and sensory impairments [18]. Nevertheless, these
mice do not show a reduction of total ceramides levels but,
contrarily, an increased generation of long-chain ceramides
[18]. Furthermore, heterozygous SPTLC1 and SPTLC2
knockout mice, which show a significantly reduced SPT
activity [19], develop no signs of a neuropathy even at
older age (Jiang X.C., personal communication). Therefore,
the actual cause for HSAN1 remains unclear. Besides, there
are further aspects of HSAN I which are enigmatic.
Although SPT is ubiquitously expressed and essential for
embryonic growth and survival [19], HSAN I is exclusively
and specifically affecting the peripheral neurons. Other
sphingolipid-rich organs like liver, lung or kidney appear
normal in HSAN I patients. In addition, no adverse effect
on the function of other neuronal tissues like the CNS was
reported in HSAN I. The patients have a normal childhood
a)
b)
226 bp
129 bp
97 bp
M
SPTLC1 p.G387A
Fig. 4 The G378A missense mutation in SPTLC1 is not necessarily
associated with HSAN I. We identified a female patient (CMT-
820.01), diagnosed with an HSAN phenotype who carried the same
c.1160G>A variation as it was originally described in the Belgian twin
(a). This sequence variation was originally tested and found to be
absent in 200 unrelated control individuals. However, segregation
analysis in the patients’ family showed that her unaffected mother
(CMT-820.03) carries the sequence variant in the homozygous state
(a). Her father (CMT-820.02), also unaffected, carries the wild-type
allele. The screening of additional 190 unrelated control individuals
revealed the presence of the G387A mutation in one of the control
individuals, confirming the low frequency of this sequence variant and
its benign character. b The c.1160G>C creates an EciI restriction site
of which its segregation is shown by PCR-RFLP analysis. The
digested PCR product of the mothers’ DNA sample shows two
fragments of 129 and 97 bp, whereas the PCR product of the fathers’
DNA sample remains intact (226 bp). M represents a 100-bp ladder
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development and the late onset of the disease in the second
or third decade suggests a rather mild noxious effect of the
mutation.
One possible explanation would be the generation of a
neurotoxic side product by the HSAN I mutants. Converse-
ly, a direct cytotoxic effect of the other HSAN I mutants on
growth or plasma membrane integrity was investigated and
excluded earlier [11]. In addition, no indication for the
generation of a toxic product was observed when express-
ing the G387A mutant in LY-B cells. Furthermore, the
HSAN I mutant overexpressing HEK293 cells showed no
signs of an impaired growth or survival due to the
generation of a toxic metabolite. Another explanation might
be the involvement of a second, yet unidentified, factor
which participates in the progression of this disease. This
could be, for instance, a potential interaction partner of SPT
or a derailed regulatory mechanism which links the mutant
SPTLC1 to the effective, but elsewhere located, pathome-
chanism. In this concept, the G387A mutation might also
be involved, albeit the mutation itself is not directly
disease-causing. In principle, all mutations found so far
may alter a specific function in the peripheral nervous
system that is currently not detected in lymphoblasts or
other cell lines. In this context, it is interesting that two
missense mutations in the RAB7 gene were reported to
cause a CMT2B neuropathy which shows similar patho-
logical features as HSAN I [20]. RAB7 belongs to the
superfamily of small GTPases and is involved in endosomal
trafficking. A possible interregulation of SPTLC1 and
RAB7 was recently put forward [21]. However, further
experiments have to be done to establish a possible
pathophysiological link between those two enzymes.
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